Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

SAN DIEGO — Po­sei­da Ther­a­peu­tics re­vealed the most com­plete da­ta so far for the al­lo­gene­ic CAR-T pro­gram that it li­censed to Roche last year. But it’s like­ly to face the ques­tion that’s dogged this field for years: Can its re­spons­es re­main durable?

On Sun­day the start­up pre­sent­ed ef­fi­ca­cy da­ta with at least four weeks of fol­low-up for its ther­a­py P-BC­MA-AL­LO1, da­ta that were “high­ly de­pen­dent” on a par­tic­u­lar part of pa­tients’ pre­con­di­tion­ing reg­i­mens, ac­cord­ing to a press re­lease. Pa­tients who took low­er lev­els of cy­clophos­phamide — an im­muno­sup­pres­sive and chemother­a­py drug — be­fore re­ceiv­ing P-BC­MA-AL­LO1 in­fu­sions did not re­spond to the CAR-T. Most of those who got high­er dos­es did re­spond.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER